Lumvoa (Veligrotug) for Thyroid Eye Disease | Ophthalmology Partners, Ltd.

Clinical Trial Results

Lumvoa was approved on the basis of two randomized, double-masked, placebo-controlled phase-3 trials: THRIVE in active TED and THRIVE-2 in chronic TED. Both dosed 5 intravenous infusions of 10 mg/kg given 3 weeks apart over about 12 weeks, with primary endpoints assessed at week 15.

THRIVE — active thyroid eye disease

Outcome (week 15)	Lumvoa	Placebo
Proptosis response (≥2 mm reduction)	70%	5%
Mean proptosis reduction	2.9 mm	0.5 mm
Mean Clinical Activity Score decrease	−3.4	−1.7
Complete diplopia resolution	54%	12%

THRIVE-2 — chronic thyroid eye disease

Outcome (week 15)	Lumvoa	Placebo
Proptosis response (≥2 mm reduction)	56%	8%
Mean proptosis reduction	2.34 mm	0.46 mm
Complete diplopia resolution	32%	—

Why chronic-disease data matters: most earlier TED therapy was studied only in recent-onset (active) disease. THRIVE-2 enrolled patients with long-standing TED (symptom onset beyond 15 months) and still showed a meaningful proptosis response, expanding the range of patients who may benefit from medical therapy before considering surgery.

Lumvoa vs. Tepezza — How the Two TED Infusions Compare

Lumvoa (veligrotug) and Tepezza (teprotumumab) are both IGF-1R–blocking antibodies given by IV infusion, and both are approved for TED regardless of activity or duration. They have not been compared head-to-head in a single trial, so the figures below come from separate studies (OPTIC for Tepezza; THRIVE/THRIVE-2 for Lumvoa) and cannot be directly equated — but they outline the practical differences.

Feature	Lumvoa (veligrotug)	Tepezza (teprotumumab)
FDA approval	June 2026	January 2020
Target	IGF-1R	IGF-1R
Infusion course	5 infusions / ~12 weeks	8 infusions / 24 weeks
Dose	10 mg/kg every 3 weeks	10 mg/kg, then 20 mg/kg every 3 weeks
Proptosis response (active)	70% (THRIVE, wk 15)	83% (OPTIC, wk 24)
Mean proptosis reduction (active)	2.9 mm	2.82 mm
Chronic-disease pivotal data	Yes (THRIVE-2)	Not in the pivotal program
Otologic (hearing) events	~16% in trial	~10% in trial (higher on formal testing)

Important: cross-trial percentages are not a head-to-head result — trial populations, endpoints, and timepoints differ (week 15 vs week 24). Both drugs share the same IGF-1R class effects, including a risk of hearing changes and elevated blood glucose. The right choice depends on disease phase, prior treatment, hearing and metabolic risk, and insurance coverage — a decision to make with an oculoplastic surgeon.

Lumvoa™ — Veligrotug Infusion

What Is Lumvoa?

How It Works

Veligrotug's Target: IGF-1R

Clinical Trial Results

THRIVE — active thyroid eye disease

THRIVE-2 — chronic thyroid eye disease

Lumvoa vs. Tepezza — How the Two TED Infusions Compare

Who Qualifies?

✓Active OR chronic TED

✓Significant proptosis or diplopia

✓Controlled thyroid function

✓Hearing & glucose risk reviewed

Treatment Protocol

Side Effects & Monitoring

Hearing changes (tinnitus, fullness, hearing loss)

Elevated blood glucose (hyperglycemia)

Infusion-related reactions, nausea, muscle spasm, fatigue

Why an Oculoplastic Surgeon for TED Care?

Discuss Lumvoa with Tamara R. Fountain, MD